Skip to main content
Enter the terms you wish to search for.
Select Search Option
This Site
All WCM Sites
Directory
Menu
Weill Cornell Medicine
Care
Discover
Teach
Jill Roberts Center for Inflammatory Bowel Disease
Explore this Website
Home
About Us
Toggle About Us menu options
Clinical Staff
Research Staff
Contact Us
Newsworthy
Toggle Newsworthy menu options
News and Announcements
Patient Care
Toggle Patient Care menu options
Clinical Services
FAQs
For Your Visit
COVID-19 Information
Nutrition Science
Toggle Nutrition Science menu options
Nutrition FAQs
Food Intolerances
News in IBD Nutrition
Research and Clinical Trials
Toggle Research and Clinical Trials menu options
Clinical Trials
Publications
Weill Cornell Medicine
Care
Discover
Teach
Home
About Us
Newsworthy
Patient Care
Nutrition Science
Research and Clinical Trials
Home
Publications
Publications
Clinical Trials
Publications
Publications
Found 5 results
Author
[
Title
]
Type
Year
Filters:
Keyword
is
Middle Aged
and
Author
is
Swaminath, Arun
[Clear All Filters]
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
D
Dulai PS
,
Boland BS
,
Singh S
,
Chaudrey K
,
Koliani-Pace JL
,
Kochhar G
,
Parikh MP
,
Shmidt E
,
Hartke J
,
Chilukuri P
et al.
. 2018.
Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease.
.
Gastroenterology. 155(3):687-695.e10.
P
Shen T-CDavid
,
Lebwohl B
,
Verma H
,
Kumta N
,
Tennyson C
,
Lewis S
,
Scherl E
,
Swaminath A
,
Capiak KM
,
DiGiacomo D
et al.
. 2012.
Peripheral neuropathic symptoms in celiac disease and inflammatory bowel disease.
.
J Clin Neuromuscul Dis. 13(3):137-45.
Shmidt E
,
Kochhar G
,
Hartke J
,
Chilukuri P
,
Meserve J
,
Chaudrey K
,
Koliani-Pace JL
,
Hirten R
,
Faleck D
,
Barocas M
et al.
. 2018.
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.
.
Inflamm Bowel Dis. 24(11):2461-2467.
S
Faleck DM
,
Winters A
,
Chablaney S
,
Shashi P
,
Meserve J
,
Weiss A
,
Aniwan S
,
Koliani-Pace JL
,
Kochhar G
,
Boland BS
et al.
. 2019.
Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.
.
Clin Gastroenterol Hepatol. 17(12):2497-2505.e1.
V
Narula N
,
Peerani F
,
Meserve J
,
Kochhar G
,
Chaudrey K
,
Hartke J
,
Chilukuri P
,
Koliani-Pace J
,
Winters A
,
Katta L
et al.
. 2018.
Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.
.
Am J Gastroenterol. 113(9):1345.